吉非替尼联合沙利度胺治疗晚期EGFR突变阳性肺腺癌患者的临床效果研究

Gefitinib combined with thalidomide in treatment of advanced EGFR mutation positive clinical effect of patients with lung adenocarcinoma

目的探讨吉非替尼联合沙利度胺治疗晚期表皮生长因子受体(EGFR)基因突变阳性肺腺癌患者的临床效果。方法回顾性分析50例EGFR基因敏感突变晚期肺腺癌患者,其中应用吉非替尼单药治疗为对照组,联合应用吉非替尼和沙利度胺治疗为观察组,每组25例,比较两组患者的肿瘤治疗效果、生存情况以及毒副作用。结果与对照组比较,观察组的总体有效率显著增高(32.00%vs 68.00%);疾病控制率显著增高(80.0%vs52.0%)。随访过程中,观察组的生存曲线较对照组明显抬高,且相关不良反应发生率显著降低。结论采用吉非替尼联合沙利度胺对EGFR基因敏感突变型肺腺癌患者治疗效果较好,不良反应降低。

Objective To investigate the effect of gefitinib combined with thalidomide in the first-line treatment of advanced pulmonary adenocarcinoma with epidermal growth factor receptor（ EGFR） gene mutation. Methods 50 cases of advanced pulmonary adenocarcinoma with EGFR mutation were analyzed,observation group（ 25 cases） was treated with gefitinib combined with thalidomide,and control group was treated with gefitinib（ 25 cases）.The clinical efficacy,survival and toxicity were compared. Results Compared to control group,the total effective rate and the disease control rate in observation group was significantly higher（ 68% vs 32%） and（ 80% vs 52%）. During the follow-up,the survival curve of the observation group was higher,but the rate of adverse reactions was lower. Conclusion Gefitinib combined with thalidomide in the first-line treatment of advanced pulmonary adenocarcinoma with EGFR mutation can effectively improve the clinical symptoms,reduce the rate of adverse reactions.